Regulation of opioid receptors by opioid antagonists: Implications for rapid opioid detoxification

Addiction Biology

Volumn 4, Issue 4, 1999, Pages 391-397

  Daws, Lynette C ^a   White, Jason M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; NALTREXOL; NALTREXONE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG OVERDOSE; HUMAN; MEDICAL ETHICS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REVIEW;

EID: 0032752095     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556219971371     Document Type: Review

References (43)

1. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995;18:22-9.
2. Reisine CA, Bell GI. Molecular biology of opioid receptors. Trends Neurosci 1993;16:506-10.
3. Matthes HWD, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996;383:819-23.
4. Gonzales JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35:192-213.
5. Takemori AE, Portoghese PS. Selective naltrexone-derived opioid receptor antagonists. Ann Rev Pharmacol Toxicol 1992;32:239-69.
6. Miotto K, McCann MJ, Rawson RA, Frosch D, Ling W. Overdose suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 1997;45:131-4.
7. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR. Naltrexone-induced opiate receptor supersensitivity. Brain Res 1982;245:285-92.
8. Bardo MT, Bhatnagar RK, Gebhart GF. Chronic naltrexone increases opiate receptor binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat. Brain Res 1983;289:223-34.
9. Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther 1985;232:439-44.
10. Yoburn BC, Goodman RR, Cohen AH, Pasternak GW, Inturrisi CE. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment. Life Sci 1985;36:2325-32.
11. Millan MJ, Morris BJ, Herz J. Antagonist-induced opioid receptor up-regulation. I. Characterisation of supersensitivity to selective mu and kappa agonists. J Pharmacol Exp Ther 1988;247:721-8.
12. Morris BJ, Millan MJ, Jerz A. Antagonist-induced opioid receptor upregulation. II. Regionally specific modulation of the mu, delta and kappa binding sites in the rat brain revealed by quantitative autoradiography. J Pharmacol Exp Ther 1988;247:729-36.
13. De Vries TJ, Tjon Tien Ril GHK, Van Der Laan JW, Mulder AH, Schoffelmeer ANM. Chronic exposure to morphine and naltrexone induces changes in catecholaminergic neuro-transmission in rat brain without altering μ-opioid receptor sensitivity. Life Sci 1993;52:1685-93.
14. Unterwald EM, Anton B, To T, Lam H, Evans CJ. Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone. Neuroscience 1998;85:897-905.
15. Tempel A, Zukin RS, Gardner EL. Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life Sci 1982;31:1401-4.
16. 3 enkephalin binding sites by different mechanisms. Neuropharmacology 1988;27:965-74.
17. Côte TE, Izenwasser S, Weems HB. Naltrexone-induced upregulation of mu opioid receptors on 7315c cell and brain membranes: enhancement of opioid efficacy in inhibiting adenylyl cylcase. J Pharmacol Exp Ther 1993;267:238-44.
18. Unterwald EM, Rubenfeld JM, Imai Y, Wang JB, Uhl GR, Kreek MJ. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Brain Res Mol Brain Res 1995;33:351-5.
19. Marley RJ, Shimosato K, Gewiss M, Thorndike E, Goldberg SR, Schindler CW. Long-term sensitisation to the behavioural effects of naltrexone is associated with regionally specific changes in the number of μ and δ opioid receptors in rat brain. Life Sci 1995;56:767-74.
20. Yoburn BC, Shah S, Chan K, Duttaroy A, Davis T. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol Biochem Behav 1995;51:535-9.
21. Bardo MT, Miller JS, Risner ME. Opiate receptor supersensitivity produced by chronic naloxone treatment: dissociation of morphine-induced antinociception and conditioned taste aversion. Pharmacol Biochem Behav 1984;21:591-7.
22. Yoburn BC, Inturrisi CE. Modification of the response to opioid and nonopioid drugs by chronic antagonist treatment. Life Sci 1988;42:1689-96.
23. Schindler CW, Wu XZ, Su T-P, Goldberg SR, Katz JL. Enhanced sensitivity to behavioural effects of naltrexone in rats. J Pharmacol Exp Ther 1990;252:8-14.
24. Brodsky M, Elliott K, Hynansky A, Inturrisi CE. CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res Bull 1995;38:135-41.
25. Castelli MP, Melis M, Mameli M, Fadda P, Diaz G, Gessa GL. Chronic morphine and naltrexone fail to modify μ-opioid receptor mRNA levels in rat brain. Brain Res Mol Brain Res 1997;45:149-53.
26. Shah S, Duttaroy A, Chen BT, Carroll J, Yoburn BC. The effect of μ-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation. Brain Res Bull 1997;42:479-84.
27. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK 293 cells. J Neurochem 1995;65:1636-45.
28. Sternini C, Spann M, Anton B, et al. Agonist-selective endocytosis of μ-opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 1996;93:9241-6.
29. Belcheva MM, Barg J, McHale RJ, Gao XM, Chuang DM, Cosscia CJ. Up-regulation of delta opioid receptors in neuroblastoma hybrid cells: evidence for differences in the mechanism of action of sodium butyrate and naltrexone. J Pharmacol Exp Ther 1991;259:302-9.
30. Bard J, Vevy R, Simantov R. Up-regulation of opiate receptors by opiate antagonists in neuroblastoma-glioma cell culture: the possibility of interaction with guanosine triphosphate-binding proteins. Neurosci Lett 1984;50;133-7.
31. Schindler CW, Marley RJ, Goldberg SR. Enhanced sensitivity to naltrexone is associated with an upregulation in GABA receptor function. Life Sci 1992;50:PL1-6.
32. Schindler CW, Goldberg SR, Katz JL. Pharmacological specificity of enhanced sensitivity to naltrexone in rats. Psychopharmacology 1993;110:60-8.
33. Gewiss MV, Marley RJ, Thorndike EB, Goldberg SR, Schindler CW. GABA receptor-linked chloride channels and the behavioural effects of naltrexone in rats. Pharmacol Biochem Behav 1994;49:589-97.
34. 2 value of naltrexone is not changed in rats following continuous exposure to morphine or naloxone. Life Sci 1992;50:1407-16.
35. Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988;29:1207-11.
36. Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: dispositions, metabolism and effects after acute and chronic dosing. Clin Pharm Ther 1996;20:315-28.
37. Wall ME, Brine DR, Perez-Reyes M. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 1981;9:369-75.
38. Meyer MC, Straughn AB, Lo M-W, Schary WL, Whitney CC. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry, 1984;45:15-19.
39. Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 1987;13:1-17.
40. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine naltrexone detoxification for opioid abusers. Br J Addict 1988;83:567-75.
41. Simon DL. Rapid opioid detoxification using opioid antagonists: history, theory and the state of the art. J Addict Dis 1997;16:103-22.
42. Johnson SM, Flemming WW. Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev 1989;41:435-88.
43. Self DW, Nestler EJ. Molecular mechanisms of drug reinforcement and addiction. Ann Rev Neurosci 1995;18:463-95.